Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

‘Positive Feedback’ Received from US FDA for COVID-19 Human Trial

Dave Jackson April 15, 2020

Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil Intravenous Formulation

GlobeNewswire April 15, 2020

The Promise of Ifenprodil - A Repurposed Drug Race for COVID-19

Livemoney April 14, 2020

Algernon CEO and CSO to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire April 13, 2020

FDA Gives Positive Response to AGN’s Phase 2 COVID-19 Trial

Stockhouse Editorial April 13, 2020

Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board

GlobeNewswire April 13, 2020

Algernon Submits Ifenprodil for COVID-19 Human Trial in South Korea

Stockhouse Editorial April 9, 2020

Algernon Announces Regulatory Submission for Ifenprodil COVID-19 Human Trial in South Korea

GlobeNewswire April 9, 2020

Health Canada Gives Positive Feedback to Algernon for Phase 2 COVID-19 Human Trial

Stockhouse Editorial April 8, 2020

Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial

GlobeNewswire April 8, 2020

Algernon Finalizes Plan for Human COVID-19 Treatment Tests

Stockhouse Editorial April 3, 2020

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

GlobeNewswire April 2, 2020

Algernon Submits Chronic Cough Drug for Ethics Approval

Stockhouse Editorial March 30, 2020

Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study

GlobeNewswire March 30, 2020

Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19

GlobeNewswire March 24, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials

GlobeNewswire March 23, 2020

IIROC Trade Resumption - AGN

Canada NewsWire March 20, 2020

IIROC Trading Halt - AGN

Canada NewsWire March 20, 2020

Algernon Appoints Novotech as CRO For Phase 2 Coronavirus Ifenprodil Trial

GlobeNewswire March 20, 2020